Elisabetta Bonzano MD, PhD· @to_be_elizabeth · X·· 1 天前评分70
正文 · 机器翻译
📌 推荐论文 2：乳腺癌，早期和晚期
在既往接受 CDK4/6i 后进展的 HR+/HER2- 晚期/转移性乳腺癌患者中，atirmociclib + fulvestrant 的疗效和安全性：一项随机 II 期研究（FOURLIGHT-1）
✨ @antgiorda
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
136 浏览 · 6 赞 · 5 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Elisabetta Bonzano MD, PhD · x.com